Last reviewed · How we verify
Manganese Sulfate (MANGANESE SULFATE)
At a glance
| Generic name | MANGANESE SULFATE |
|---|---|
| Sponsor | Abraxis Pharm |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
Key clinical trials
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- Effect of Probiotics After Neurosurgery (NA)
- Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study (NA)
- Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection (NA)
- Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety (PHASE4)
- Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN (PHASE4)
- 2021 PMT iAge® Intervention Trial by Edifice Health (NA)
- Prenatal Iodine Supplementation and Early Childhood Neurodevelopment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Manganese Sulfate CI brief — competitive landscape report
- Manganese Sulfate updates RSS · CI watch RSS